<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863079</url>
  </required_header>
  <id_info>
    <org_study_id>E20210220A</org_study_id>
    <nct_id>NCT04863079</nct_id>
  </id_info>
  <brief_title>Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )</brief_title>
  <official_title>Pembrolizumab for Adjuvant Treatment After R0 Resection of Thoracic ESCC Patients With Lymph Node Positive: A Single-arm, Open-label, PhaseⅡTrial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe and evaluate the efficacy and safety of postoperative&#xD;
      adjuvant treatment of pembrolizumab in patients with thoracic esophageal squamous cell&#xD;
      carcinoma （ESCC） who have not received neoadjuvant therapy before undergoing R0 resection,&#xD;
      and have positive postoperative lymph nodes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients with thoracic esophageal squamous cell carcinoma （ESCC） who have undergone R0&#xD;
      resection, have not received neoadjuvant therapy, and have positive postoperative lymph&#xD;
      nodes, there is no international consensus on whether postoperative adjuvant therapy is&#xD;
      required. The JCOG9204 study reported that for patients with ESCC with positive lymph nodes&#xD;
      after R0 resection, postoperative adjuvant chemotherapy can improve the disease-free survival&#xD;
      (DFS) of the ESCC patients. However, due to the adverse effects of chemotherapy, patients are&#xD;
      often difficult to tolerate. We designed a single-arm, open-label, phase II trial of&#xD;
      pembrolizumab for adjuvant treatment after R0 resection of thoracic ESCC Patients with lymph&#xD;
      node positive. The purpose of this study is to observe and evaluate the efficacy and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Time from the enrollment to death of any cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Time from the enrollment to disease relapse after complete resection or death from any cause</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>ESCC</condition>
  <condition>Adjuvant Treatment</condition>
  <condition>Lymph Node Positive</condition>
  <condition>Pembrolizumab</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab for Postoperative Adjuvant Treatment of ESCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance as postoperative adjuvant treatment of ESCC with pN+.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Injection [Keytruda]</intervention_name>
    <description>Pembrolizumab 200 mg IV, Q3W, up to one year or disease progression or intolerance.</description>
    <arm_group_label>Pembrolizumab for Postoperative Adjuvant Treatment of ESCC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed ESCC;&#xD;
&#xD;
          2. Patients have not received neoadjuvant therapy.&#xD;
&#xD;
          3. Thoracic ESCC with R0 resection and positive postoperative lymph nodes;&#xD;
&#xD;
          4. Have a performance status of 0 or 1 on the ECOG Performance Scale;&#xD;
&#xD;
          5. Age 18-70 years old, both men and women;&#xD;
&#xD;
          6. Be willing and able to provide written informed consent/assent for the trial;&#xD;
&#xD;
          7. Demonstrate adequate organ function , all screening labs should be performed within 10&#xD;
             days of treatment initiation;&#xD;
&#xD;
          8. Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required;&#xD;
&#xD;
          9. Be willing to provide postoperative tissue specimens. After tumor recurrence, continue&#xD;
             to be willing to provide tissue samples such as needle biopsy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neoadjuvant therapy (radiotherapy, immunotherapy, or chemotherapy) for ESCC;&#xD;
&#xD;
          2. Non-R0 resection for ESCC;&#xD;
&#xD;
          3. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days prior to the first dose of study drug;&#xD;
&#xD;
          4. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs);&#xD;
&#xD;
          5. Has severe hypersensitivity and adverse events (≥Grade 3) to pembrolizumab and/or any&#xD;
             PD-1/PD-L1 inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dingzhi Huang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongjing Jiang, MD, PhD</last_name>
    <phone>+8618622221069</phone>
    <email>jianghongjing@tmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chuangui Chen, MD, PhD</last_name>
    <phone>+8618622228653</phone>
    <email>ccg209@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongjing Jiang, MD, PhD</last_name>
      <phone>+8618622221069</phone>
      <email>jianghongjing@tmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Chuangui Chen, MD, PhD</last_name>
      <phone>+8618622228653</phone>
      <email>ccg209@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

